		Application No.	Appliagnt(a)	
Office Action Summary		Application No.	Applicant(s)	
		10/593,432	MAUNDRELL, KINSEY	
		Examiner	Art Unit	
		MICHELLE HORNING	1648	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).				
Status				
1)🛛	Responsive to communication(s) filed on 18 Se	eptember 2006.		
2a) <u></u> ☐	This action is FINAL . 2b) ☐ This	action is non-final.		
3)	/			
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4)🖂	☑ Claim(s) <u>28-45</u> is/are pending in the application.			
•	4a) Of the above claim(s) is/are withdrawn from consideration.			
5)	5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected.			
	7) Claim(s) is/are objected to.			
8) Claim(s) <u>28-45</u> are subject to restriction and/or election requirement.				
Application Papers				
9)☐ The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).				
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:				
 Certified copies of the priority documents have been received. 				
2. Certified copies of the priority documents have been received in Application No				
3. Copies of the certified copies of the priority documents have been received in this National Stage				
application from the International Bureau (PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list of the certified copies not received.				
Attachmen	t(s)	_		
	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔯 Interview Summary Paper No(s)/Mail Da		
3) Infor	re of Draftsperson's Patent Drawing Review (P10-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	5) Notice of Informal P		

DETAILED ACTION

Note that the last action has been vacated in favor of this action due to an error on the previous Office Action Summary. The period for reply has been corrected to 1 month.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 28-39, drawn to methods of generating an antibody and compositions comprising such antibodies, including compositions comprising specific antibodies.

Group II, claim(s) 40-45, drawn to methods of using specific antibodies for treatment and PrPsc detection.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Claims 29-34 is directed to an invention which lacks novelty. More specifically, lipid raft immunization is taught by the prior art; see cited reference WO 03/048302 (hereinafter as "Tso"). See page 6 in which the descriptions of the figures provide different lipid raft hybridomas to multiple cancer lines. Separately, Applicants provided additional prior art that is related to the claimed invention. It is noted that prion proteins are localized to such rafts as described by Enari (2001-cited) and Bosque and Prusiner (2000-cited) provide that

Art Unit: 1648

ScN2a is the most useful cell line for studying the cell biology of prion replication (see Introduction). Thus, no special technical feature exists for the Groups I and II as defined by PCT Rule 13.2, because it does not define a contribution over the prior art. Note that PCT Rule 13 does not provide for multiple products or methods within a single application. Because the technical special feature of the Groups is not a special technical feature, unity of invention is lacking.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during

Art Unit: 1648

prosecution to require the limitations of the product claims. **Failure to do so may result** in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHELLE HORNING whose telephone number is (571)272-9036. The examiner can normally be reached on Monday-Friday 8:00-5:00 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/593,432 Page 5

Art Unit: 1648

Patent Examiner

/Gary B. Nickol / Supervisory Patent Examiner, Art Unit 1646